Rebecca L. Stone, MD

Dermatologic Toxicity in a Patient Receiving Liposomal Doxorubicin

Publish date: February 9, 2015

Liposomal doxorubicin hydrochloride is an anthracycline topoisomerase inhibitor indicated for ovarian cancer, AIDS-related Kaposi sarcoma, and mul...